阿片类药物滥用 后果触目惊心

2016-12-12 迟丽波(编译) 健康界

有多少阿片类镇痛药最终走成了反派,由治病变成致命。本文抛出了7个数值,勾勒出阿片药是怎样背道而驰的。2016年11月,美国联邦公共卫生署(Surgeon General)公布一份名为《面对美国成瘾症》的研究报告。今时今日,酗酒和毒品已然成为了架在美国民众脖子上的一柄钢刀,威胁着国民的健康与生命,而造成这一危机的幕后推手就是那一张张开有阿片类药物的处方单。@ 美国物质滥用与心理健康服务局(U.S.

有多少阿片类镇痛药最终走成了反派,由治病变成致命。本文抛出了7个数值,勾勒出阿片药是怎样背道而驰的。



2016年11月,美国联邦公共卫生署(Surgeon General)公布一份名为《面对美国成瘾症》的研究报告。今时今日,酗酒和毒品已然成为了架在美国民众脖子上的一柄钢刀,威胁着国民的健康与生命,而造成这一危机的幕后推手就是那一张张开有阿片类药物的处方单。

@ 美国物质滥用与心理健康服务局(U.S. Substance Abuse and Mental Health Services Administration) 调查:12岁以上滥用阿片类镇痛药的美国民众高达1900万人。

@ 艾美仕医疗信息研究所(IMS Institute for Healthcare Informatics): 2014年阿片类镇痛药处方总数达2.21亿,2015年达2.04亿。

@ 美国医疗健康软件开发商Castlight Health:阿片类药物滥用患者平均每年的医疗费用为1.945万美元,而一般患者为1.0853万美元。

@ 美国医疗健康软件开发商Castlight Health:医疗保险支付阿片类药物的费用中,32%并没有起到作用,这一部分费用本可以省下来。

@ 美国疾病预防控制中心(Centers for Diseases Control and Prevention, CDC):4.7055名患者因药物过量致死,其中处方镇痛药居多,所占比例高达40%。

@ 美国国立药物滥用研究所(National Institute on Drug Abuse, NIDA):阿片类药物的处方数量全球排名中,美国居首。

这7个数字勾勒出一条清晰明朗的因果链,影射出来的信息触目惊心,让人无法回避。阿片类药物滥用者人数众多,处方单数量庞大,导致医疗支出增加,远高于一般患者。其近三成的医保支出也打了水漂,不仅没有给民众的健康带来福祉,反而使很多人因阿片类药物过量而致死。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701534, encodeId=23081e015347a, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Thu Jun 22 17:49:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253020, encodeId=16a41253020a5, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309035, encodeId=43e91309035d0, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443230, encodeId=c9b9144323024, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=)]
    2017-06-22 zchen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701534, encodeId=23081e015347a, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Thu Jun 22 17:49:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253020, encodeId=16a41253020a5, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309035, encodeId=43e91309035d0, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443230, encodeId=c9b9144323024, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1701534, encodeId=23081e015347a, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Thu Jun 22 17:49:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253020, encodeId=16a41253020a5, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309035, encodeId=43e91309035d0, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443230, encodeId=c9b9144323024, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=)]
    2016-12-14 lhlxtx
  4. [GetPortalCommentsPageByObjectIdResponse(id=1701534, encodeId=23081e015347a, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Thu Jun 22 17:49:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253020, encodeId=16a41253020a5, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309035, encodeId=43e91309035d0, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443230, encodeId=c9b9144323024, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Dec 14 01:49:00 CST 2016, time=2016-12-14, status=1, ipAttribution=)]

相关资讯

Ann Surg:一般外科手术后,适合多少阿片类药物处方?

目的:调查一般外科手术后,阿片类药物的处方模式,并估计出理想的处方数量。背景:阿片类药物使用过量会导致死亡率的增加,关于一般外科手术后,阿片类药物处方的最佳剂量的数据是缺乏的。方法:我们对来自5个门诊部门的642例患者进行了评估:部分乳房切除术(PM)、部分乳房切除术+前哨淋巴结活检(PM SLNB)、腹腔镜胆囊切除术(LC)、腹腔镜腹股沟疝修补术(LiH)和开放式腹股沟疝修补术(IH)。获取患者

Science:镇痛剂“失效”了?痛觉过敏是主谋!

常言道,牙疼不是病,疼起来要人命。想来很多人对牙痛的滋味体悟甚深,而人之一生,换句话说就是疼痛的一生。痛是生命历程中不可或缺的生理与心理感受。但逐乐避痛是人的天性,也是近些年来止痛剂层出不穷的原因。近日Science一篇文章认为止痛剂的效果其实并没有想象中那么好,有时甚至加剧疼痛。那么这背后的真相到底如何,让我们一睹为快。痛觉过敏(OIH)澳大利亚阿德莱德大学的研究人员Mark Hutchin

MMWR:美国新生儿戒断综合征患病率增加了300%!

Morbidity and Mortality Weekly Report(MMWR)上发布的数据显示,28个州新生儿戒断综合征(NAS)的总患病率从1999年至2013年,增加了300%。强调了防止不必要的阿片类药物使用的公共卫生计划的重要性,以及孕期治疗物质使用障碍的重要性。来自CDC国家慢性病预防和健康促进中心的Jean Y. Ko博士对1999至2013年的相关数据库进行了分析,探究NAS

NEJM:纳屈酮缓释剂对预防阿片类复吸的作用

环丙甲羟二羟吗啡酮缓释剂是一种持续释放的每月注射一次的μ-阿片受体拮抗剂,对预防阿片类依赖的复吸有效。在美国刑事审判人群中支持其有效性的数据不足。

NEJM:Naloxegol可治疗阿片类药物引发的便秘

《新英格兰医学杂志》(NEJM)2014年6月4日在线发表的研究显示,一种新药Naloxegol 可以减少非癌症疼痛患者阿片类药物引发的便秘(opioid-induced constipation,OIC)的发生。这篇论文包括两项多中心随机对照研究。  该研究在美国和欧洲进行,共纳入近1400名成人患者,这些患者至少口服4周阿片用于治疗非癌症疼痛,并且已被确诊为伴有O